Determination of mild, moderate, and severe pain interference in patients with cancer

Qiuling Shi, Tito R. Mendoza, Amylou Dueck, Haijun Ma, Jeffrey Zhang, Yi Qian, Debajyoti Bhowmik, Charles S. Cleeland

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Effective assessment and management of pain in patients with cancer is strengthened by the patient's report of how much pain interferes with daily functioning. This requires a clear delineation of different levels of pain interference. We derived optimal cutpoints for differentiating between mild, moderate, and severe pain interference assessed by the Brief Pain Inventory (BPI) and describe the prevalence and characteristics of pain-induced functional impairment in patients with cancer. Data were pooled across 3 Phase III pivotal trials. Patient-completed questionnaires included the EuroQol 5 dimensions questionnaire (EQ5D), Functional Assessment of Cancer Therapy-General Measure (FACT-G), and BPI. Optimal cutpoints for categorizing pain interference into 3 levels were derived using analysis of variance, with different cutpoint sets for BPI total interference (BPI-PITS, the average score of all 7 items), activity-related interference (BPI-WAW, the average score of work, general activity, and walking), and mood-related interference (BPI-REM, the average score of relations with others, enjoyment of life, and mood) as independent variables and EQ5D-visual analog scale and total FACT-G score as dependent variables. To validate the cutpoints, we assessed whether interference categories were in concordance with Eastern Cooperative Oncology Group performance status (ECOG-PS) levels. The optimal cutpoints were (2,5) for BPI-PITS, (2,6) for BPI-WAW, and (2,5) for BPI-REM. The mild (<2), moderate (2-5 or 2-6), and severe (>5 or >6) pain interference groups were significantly concordant with ECOG-PS levels (P < 0.0001). We empirically derived patient-reported pain interference categories in relation to clinician-rated performance status. These cutpoints may facilitate the conduct and interpretation of clinical evaluation, symptom epidemiology, and clinical trials.

Original languageEnglish (US)
Pages (from-to)1108-1112
Number of pages5
JournalPain
Volume158
Issue number6
DOIs
StatePublished - Jun 1 2017

Fingerprint

Pain
Neoplasms
Equipment and Supplies
Symptom Assessment
Pain Measurement
Pain Management
Visual Analog Scale
Walking
Analysis of Variance
Epidemiology
Clinical Trials
Therapeutics

Keywords

  • Assessment
  • Brief Pain Inventory
  • Cutpoints
  • Functioning
  • Interference
  • Patient-reported outcomes
  • Severity

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Cite this

Shi, Q., Mendoza, T. R., Dueck, A., Ma, H., Zhang, J., Qian, Y., ... Cleeland, C. S. (2017). Determination of mild, moderate, and severe pain interference in patients with cancer. Pain, 158(6), 1108-1112. https://doi.org/10.1097/j.pain.0000000000000890

Determination of mild, moderate, and severe pain interference in patients with cancer. / Shi, Qiuling; Mendoza, Tito R.; Dueck, Amylou; Ma, Haijun; Zhang, Jeffrey; Qian, Yi; Bhowmik, Debajyoti; Cleeland, Charles S.

In: Pain, Vol. 158, No. 6, 01.06.2017, p. 1108-1112.

Research output: Contribution to journalArticle

Shi, Q, Mendoza, TR, Dueck, A, Ma, H, Zhang, J, Qian, Y, Bhowmik, D & Cleeland, CS 2017, 'Determination of mild, moderate, and severe pain interference in patients with cancer', Pain, vol. 158, no. 6, pp. 1108-1112. https://doi.org/10.1097/j.pain.0000000000000890
Shi, Qiuling ; Mendoza, Tito R. ; Dueck, Amylou ; Ma, Haijun ; Zhang, Jeffrey ; Qian, Yi ; Bhowmik, Debajyoti ; Cleeland, Charles S. / Determination of mild, moderate, and severe pain interference in patients with cancer. In: Pain. 2017 ; Vol. 158, No. 6. pp. 1108-1112.
@article{e929401afefc41b98165d4abe73dcab8,
title = "Determination of mild, moderate, and severe pain interference in patients with cancer",
abstract = "Effective assessment and management of pain in patients with cancer is strengthened by the patient's report of how much pain interferes with daily functioning. This requires a clear delineation of different levels of pain interference. We derived optimal cutpoints for differentiating between mild, moderate, and severe pain interference assessed by the Brief Pain Inventory (BPI) and describe the prevalence and characteristics of pain-induced functional impairment in patients with cancer. Data were pooled across 3 Phase III pivotal trials. Patient-completed questionnaires included the EuroQol 5 dimensions questionnaire (EQ5D), Functional Assessment of Cancer Therapy-General Measure (FACT-G), and BPI. Optimal cutpoints for categorizing pain interference into 3 levels were derived using analysis of variance, with different cutpoint sets for BPI total interference (BPI-PITS, the average score of all 7 items), activity-related interference (BPI-WAW, the average score of work, general activity, and walking), and mood-related interference (BPI-REM, the average score of relations with others, enjoyment of life, and mood) as independent variables and EQ5D-visual analog scale and total FACT-G score as dependent variables. To validate the cutpoints, we assessed whether interference categories were in concordance with Eastern Cooperative Oncology Group performance status (ECOG-PS) levels. The optimal cutpoints were (2,5) for BPI-PITS, (2,6) for BPI-WAW, and (2,5) for BPI-REM. The mild (<2), moderate (2-5 or 2-6), and severe (>5 or >6) pain interference groups were significantly concordant with ECOG-PS levels (P < 0.0001). We empirically derived patient-reported pain interference categories in relation to clinician-rated performance status. These cutpoints may facilitate the conduct and interpretation of clinical evaluation, symptom epidemiology, and clinical trials.",
keywords = "Assessment, Brief Pain Inventory, Cutpoints, Functioning, Interference, Patient-reported outcomes, Severity",
author = "Qiuling Shi and Mendoza, {Tito R.} and Amylou Dueck and Haijun Ma and Jeffrey Zhang and Yi Qian and Debajyoti Bhowmik and Cleeland, {Charles S.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1097/j.pain.0000000000000890",
language = "English (US)",
volume = "158",
pages = "1108--1112",
journal = "Pain",
issn = "0304-3959",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Determination of mild, moderate, and severe pain interference in patients with cancer

AU - Shi, Qiuling

AU - Mendoza, Tito R.

AU - Dueck, Amylou

AU - Ma, Haijun

AU - Zhang, Jeffrey

AU - Qian, Yi

AU - Bhowmik, Debajyoti

AU - Cleeland, Charles S.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Effective assessment and management of pain in patients with cancer is strengthened by the patient's report of how much pain interferes with daily functioning. This requires a clear delineation of different levels of pain interference. We derived optimal cutpoints for differentiating between mild, moderate, and severe pain interference assessed by the Brief Pain Inventory (BPI) and describe the prevalence and characteristics of pain-induced functional impairment in patients with cancer. Data were pooled across 3 Phase III pivotal trials. Patient-completed questionnaires included the EuroQol 5 dimensions questionnaire (EQ5D), Functional Assessment of Cancer Therapy-General Measure (FACT-G), and BPI. Optimal cutpoints for categorizing pain interference into 3 levels were derived using analysis of variance, with different cutpoint sets for BPI total interference (BPI-PITS, the average score of all 7 items), activity-related interference (BPI-WAW, the average score of work, general activity, and walking), and mood-related interference (BPI-REM, the average score of relations with others, enjoyment of life, and mood) as independent variables and EQ5D-visual analog scale and total FACT-G score as dependent variables. To validate the cutpoints, we assessed whether interference categories were in concordance with Eastern Cooperative Oncology Group performance status (ECOG-PS) levels. The optimal cutpoints were (2,5) for BPI-PITS, (2,6) for BPI-WAW, and (2,5) for BPI-REM. The mild (<2), moderate (2-5 or 2-6), and severe (>5 or >6) pain interference groups were significantly concordant with ECOG-PS levels (P < 0.0001). We empirically derived patient-reported pain interference categories in relation to clinician-rated performance status. These cutpoints may facilitate the conduct and interpretation of clinical evaluation, symptom epidemiology, and clinical trials.

AB - Effective assessment and management of pain in patients with cancer is strengthened by the patient's report of how much pain interferes with daily functioning. This requires a clear delineation of different levels of pain interference. We derived optimal cutpoints for differentiating between mild, moderate, and severe pain interference assessed by the Brief Pain Inventory (BPI) and describe the prevalence and characteristics of pain-induced functional impairment in patients with cancer. Data were pooled across 3 Phase III pivotal trials. Patient-completed questionnaires included the EuroQol 5 dimensions questionnaire (EQ5D), Functional Assessment of Cancer Therapy-General Measure (FACT-G), and BPI. Optimal cutpoints for categorizing pain interference into 3 levels were derived using analysis of variance, with different cutpoint sets for BPI total interference (BPI-PITS, the average score of all 7 items), activity-related interference (BPI-WAW, the average score of work, general activity, and walking), and mood-related interference (BPI-REM, the average score of relations with others, enjoyment of life, and mood) as independent variables and EQ5D-visual analog scale and total FACT-G score as dependent variables. To validate the cutpoints, we assessed whether interference categories were in concordance with Eastern Cooperative Oncology Group performance status (ECOG-PS) levels. The optimal cutpoints were (2,5) for BPI-PITS, (2,6) for BPI-WAW, and (2,5) for BPI-REM. The mild (<2), moderate (2-5 or 2-6), and severe (>5 or >6) pain interference groups were significantly concordant with ECOG-PS levels (P < 0.0001). We empirically derived patient-reported pain interference categories in relation to clinician-rated performance status. These cutpoints may facilitate the conduct and interpretation of clinical evaluation, symptom epidemiology, and clinical trials.

KW - Assessment

KW - Brief Pain Inventory

KW - Cutpoints

KW - Functioning

KW - Interference

KW - Patient-reported outcomes

KW - Severity

UR - http://www.scopus.com/inward/record.url?scp=85019964401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019964401&partnerID=8YFLogxK

U2 - 10.1097/j.pain.0000000000000890

DO - 10.1097/j.pain.0000000000000890

M3 - Article

C2 - 28267060

AN - SCOPUS:85019964401

VL - 158

SP - 1108

EP - 1112

JO - Pain

JF - Pain

SN - 0304-3959

IS - 6

ER -